Enovis (NYSE:ENOV) Stock Rating Lowered by Wall Street Zen

Enovis (NYSE:ENOV) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Saturday.

A number of other analysts have also recently commented on the company. Zacks Research raised Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. Wells Fargo & Company raised Enovis to a “strong-buy” rating in a research report on Wednesday, March 18th. Needham & Company LLC lifted their price target on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. William Blair initiated coverage on Enovis in a research report on Friday, April 17th. They set an “outperform” rating for the company. Finally, Evercore reaffirmed an “outperform” rating on shares of Enovis in a research report on Monday, January 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $47.43.

Enovis Stock Performance

Shares of ENOV opened at $23.58 on Friday. The stock has a 50-day moving average of $23.70 and a two-hundred day moving average of $25.93. Enovis has a one year low of $21.00 and a one year high of $37.85. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The stock has a market cap of $1.36 billion, a P/E ratio of -1.14 and a beta of 1.41.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.95 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company had revenue of $575.76 million during the quarter, compared to analysts’ expectations of $584.30 million. During the same quarter in the previous year, the firm posted $0.98 EPS. The firm’s revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts predict that Enovis will post 3.62 EPS for the current year.

Insider Activity

In related news, insider Oliver Engert acquired 1,000 shares of the firm’s stock in a transaction dated Friday, February 27th. The stock was acquired at an average price of $25.50 per share, with a total value of $25,500.00. Following the acquisition, the insider directly owned 43,640 shares in the company, valued at $1,112,820. This represents a 2.35% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders bought 5,000 shares of company stock valued at $121,983. Insiders own 2.90% of the company’s stock.

Hedge Funds Weigh In On Enovis

Several institutional investors and hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp lifted its holdings in shares of Enovis by 50,442.8% in the 1st quarter. Fifth Third Bancorp now owns 83,901 shares of the company’s stock valued at $1,909,000 after buying an additional 83,735 shares during the period. Bernzott Capital Advisors lifted its holdings in shares of Enovis by 47.4% in the 1st quarter. Bernzott Capital Advisors now owns 294,125 shares of the company’s stock valued at $6,691,000 after buying an additional 94,529 shares during the period. Counterpoint Mutual Funds LLC acquired a new position in shares of Enovis in the 1st quarter valued at about $564,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Enovis in the 1st quarter valued at about $429,000. Finally, Inspire Investing LLC acquired a new position in shares of Enovis in the 1st quarter valued at about $523,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.